Polomar Health Services, Inc. operates a licensed retail compounding pharmacy in Palm Harbor, Florida that prepares sterile and non sterile custom medications for patients across twenty eight states. The company also owns SlimRx, an online platform that connects patients with licensed physicians to prescribe weight loss treatments, and it is preparing to launch PoloMeds, a service focused on diabetes, erectile dysfunction and dermatological prescriptions. In addition,…
Polomar Health Services, Inc. operates a licensed retail compounding pharmacy in Palm Harbor, Florida that prepares sterile and non sterile custom medications for patients across twenty eight states. The company also owns SlimRx, an online platform that connects patients with licensed physicians to prescribe weight loss treatments, and it is preparing to launch PoloMeds, a service focused on diabetes, erectile dysfunction and dermatological prescriptions. In addition, Polomar provides prescription fulfillment services to third party telehealth platforms on a wholesale basis.
Revenue is generated primarily from the sale of compounded prescription medications dispensed through its pharmacy. Additional income comes from consultation and service fees collected via the SlimRx platform for weight loss treatment programs. The forthcoming PoloMeds service is expected to generate revenue from diabetes, erectile dysfunction and dermatological prescription sales once launched. The company also earns fees from providing prescription fulfillment services to third party telehealth platforms on a wholesale basis.
Polomar Health Services, Inc. operates in the niche markets of sterile compounding pharmacy and digital health telehealth services. It faces competition from established compounding pharmacies such as Fagron and PCCA, as well as from telehealth companies like Ro and Hims & Hers that offer prescription fulfillment. Its competitive advantages include holding a special sterile compounding permit that allows it to dispense injectable medications, maintaining licenses in twenty eight states with plans to expand to most U. S. states by the end of twenty twenty five, and possessing a worldwide non exclusive license to use patent pending technology for delivering medications containing metformin, eletriptan, semaglutide, liraglutide and sildenafil.
The company serves patients who seek custom compounded medications, individuals looking for weight loss therapies through SlimRx, and future clients needing diabetes, erectile dysfunction or dermatological treatments via PoloMeds. It also provides services to third party telehealth platforms that require a reliable prescription fulfillment partner.